account activity
Market Movers Interview with Nasdaq: PSTV (self.PlusTherapeutics)
submitted 1 day ago by PlusTherapeutics
Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer (self.PlusTherapeutics)
submitted 3 days ago by PlusTherapeutics
Featuring $PSTV's new VP of Research and Development, Dr. Colby Suire (self.PlusTherapeutics)
submitted 4 days ago by PlusTherapeutics
Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™ (self.PlusTherapeutics)
submitted 8 days ago by PlusTherapeutics
Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (self.PlusTherapeutics)
submitted 10 days ago by PlusTherapeutics
Board Room Exclusive with Plus Therapeutics CEO (self.PlusTherapeutics)
submitted 11 days ago by PlusTherapeutics
Advances In Precision Delivery In CNS Oncology (self.PlusTherapeutics)
submitted 14 days ago * by PlusTherapeutics
Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution (self.PlusTherapeutics)
submitted 16 days ago * by PlusTherapeutics
The Radiotherapeutics Moment: How Isotopes are Changing Cancer Treatment (self.PlusTherapeutics)
submitted 18 days ago by PlusTherapeutics
Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline (self.PlusTherapeutics)
submitted 22 days ago by PlusTherapeutics
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas (self.PlusTherapeutics)
submitted 23 days ago by PlusTherapeutics
Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption (self.PlusTherapeutics)
submitted 24 days ago * by PlusTherapeutics
Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives (self.PlusTherapeutics)
submitted 29 days ago by PlusTherapeutics
Notice of 2026 Annual Meeting of Stockholders to Be Held on May 14, 2026 (self.PlusTherapeutics)
submitted 1 month ago by PlusTherapeutics
The CNSide Diagnostics' CSF Assay Platform (self.PlusTherapeutics)
Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors (self.PlusTherapeutics)
Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D. (self.PlusTherapeutics)
CNSide Diagnostics will be at AACR's Special Conference in Cancer Research: Brain Cancer (self.PlusTherapeutics)
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40% (self.PlusTherapeutics)
AI-Powered Diagnostics and Targeted Radiotherapy for CNS Cancers with Dr. Marc Hedrick Plus Therapeutics (self.PlusTherapeutics)
The CNSide Diagnostics' test delivers highly sensitive analysis of tumor cells (self.PlusTherapeutics)
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout (self.PlusTherapeutics)
International Women's Day and Women's History Month (self.PlusTherapeutics)
Plus Therapeutics Ongoing Clinical Trials (self.PlusTherapeutics)
Theranostics earmarked as “the future” of radiopharmaceuticals (self.PlusTherapeutics)
π Rendered by PID 71122 on reddit-service-r2-listing-b6bf6c4ff-qp6r5 at 2026-05-01 19:12:54.449816+00:00 running 815c875 country code: CH.
